https://doi.org/10.55788/98bdc987
“Lung cancer has been associated with sexual dysfunction,” said Dr Narjust Florez (Dana Farber Cancer Institute, MA, USA) [2]. “However, these data mostly stem from the pre-immune checkpoint inhibitor-era, and sexual health in lung cancer is therefore a currently understudied topic.” Dr Florez and colleagues assessed the prevalence of sexual dysfunction in women with lung cancer via a validated online questionnaire. The observational SHAWL study included 249 participants, with ages ranging from 29–84 years.
Moderate to severe sexual dysfunction was reported in 77% of the participating women. In addition, 59% of the participants who had sexual activity in the last 30 days reported issues with vaginal dryness and 26% of all responders noted complaints of vaginal pain or discomfort during sexual activity. Furthermore, there was a marked difference in decreased sexual interest before and after the diagnosis of lung cancer (15% vs 31%; P<0.001). Finally, reasons for a reduced satisfaction of patients with their sex life included fatigue (40%), sadness/unhappiness (28%), issues with partner (22%), and shortness of breath (15%).
- Florez N, et al. Sexual Health Assessment in Women with Lung Cancer (SHAWL) study. MA14.04, WCLC 2022, Vienna, Austria, 06–09 August.
- Bober SL, et al. J Clin Oncol. 2012 Oct 20;30(30):3712-9.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
Do we underestimate the effect of air pollution on lung cancer incidence? »
« Letter from the Editor Next Article
Do we underestimate the effect of air pollution on lung cancer incidence? »
Table of Contents: WCLC 2022
Featured articles
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
WCLC 2022 Congress Round-Up
Sugemalimab offers PFS benefits for unresectable NSCLC
First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
NADIM: Risk of progression identified through RNA sequencing
NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC
POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?
First DLL3-targeted therapy shows promise in SCLC
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC
Talazoparib plus temozolomide appears efficacious in ES-SCLC
Pembrolizumab plus lenvatinib performs well in MPM
Early detection strategies in younger patients with lung cancer are urgently needed
Intensive co-located smoking cessation programme highly effective during lung screening
Do we underestimate the effect of air pollution on lung cancer incidence?
Interventions needed to address sexual health in lung cancer
Related Articles
August 12, 2021
Patritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC
June 25, 2019
Other I-O combinations
January 29, 2021
Lung-cancer salvage surgery might help after TKI treatment
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com